Table 3.

Summary of studies on everolimus combined with SSAs

Study	Objects	Setting	Treatment and dose	mPFS
RADIANT-1 (86)	Pancreatic NET	Non-randomized phaseIIstudy	Everolimus plus octreotide LAR vs. everolimus	16.7 vs. 9.7 m
RADIANT-2 (89)	GI-NET (functioning)	Randomized phase III study	Everolimus plus octreotide LAR vs. everolimus	16.0 m
EVERLAR (85)	GI-NET	Single-arm phaseIIstudy	Everolimus plus octreotide LAR	20.3 m
ITMO (86)	Pancreas/GI/lung	Single-arm phaseIIstudy	Everolimus plus octreotide LAR	33.6 m
STARTER-NET (88)	GEP-NET	Randomized phase III study	Everolimus vs. everolimus plus lanreotide	Ongoing

SSAs, somatostatin analogs; GI, gastrointestinal; GEP-NET, gastroenteropancreatic neuroendocrine tumor; LAR, long-acting release.